Provided by Tiger Trade Technology Pte. Ltd.

Haemonetics

105.90
-0.4150-0.39%
Volume:174.23K
Turnover:18.34M
Market Cap:4.81B
PE:51.66
High:106.87
Open:105.11
Low:103.24
Close:106.31
52wk High:109.57
52wk Low:47.32
Shares:45.45M
Float Shares:44.60M
Volume Ratio:0.37
T/O Rate:0.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.05
EPS(LYR):2.05
ROE:11.20%
ROA:6.60%
PB:5.75
PE(LYR):51.66

Loading ...

Haemonetics’ Vascade MVP system shows efficacy in electrophysiology study

TIPRANKS
·
Aug 04

Haemonetics Study Shows Vascade MVP XL Posts 1.2% Vascular Complications in 1,623 Large-Bore Electrophysiology Cases

Reuters
·
Aug 04

Earning Preview: Haemonetics revenue is expected to increase by 7.73%, and institutional views are moderately positive

Earnings Agent
·
Jul 31

Haemonetics price target raised to $93 from $80 at BofA

TIPRANKS
·
Jul 29

Haemonetics Adds Veteran Director as Shareholders Back Governance

TIPRANKS
·
Jul 29

Haemonetics Director Martin D. Madaus Files Initial Beneficial Ownership Statement

Reuters
·
Jul 29

Haemonetics Adds Carlyle Operating Executive Martin Madaus to Board

Reuters
·
Jul 29

Martin Madaus Elected to Haemonetics Board of Directors

THOMSON REUTERS
·
Jul 29

Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema

GlobeNewswire
·
Jul 22

Haemonetics Updates Financial Calendar with Q1 Fiscal 2027 Results Release and Earnings Call Scheduled

Reuters
·
Jul 09

Press Release: Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026

Dow Jones
·
Jul 09

Citi adds ‘downside 90-day catalyst watch’ on Haemonetics

TIPRANKS
·
Jul 08

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

GlobeNewswire
·
Jul 06

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

GlobeNewswire
·
Jun 29

Haemonetics Price Target Maintained with a $84.00/share by BTIG

Dow Jones
·
Jun 26

Analysts Conflicted on These Healthcare Names: Haemonetics (HAE) and Health Catalyst (HCAT)

TIPRANKS
·
Jun 26

Pharvaris (PHVS) Is Up 6.0% After Strong Phase 3 Oral HAE Data With Novel Endpoint Introduction

Simply Wall St.
·
Jun 19

Haemonetics Price Target Maintained With a $84.00/Share by BTIG

Dow Jones
·
Jun 17

Haemonetics management to meet virtually with BTIG

TIPRANKS
·
Jun 17

Intellia Highlights Strong Phase 3 Lonvo-z HAE Results

TIPRANKS
·
Jun 15